Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Modafinil is a wakefulness-promoting agent and central nervous system (CNS) stimulant used primarily to treat excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome (OSAHS), and shift work sleep disorder. It is a racemic compound taken orally, available as 100 mg and 200 mg tablets. The precise mechanism of action remains unclear, but modafinil is believed to promote wakefulness by altering the concentrations of certain neurotransmitters in the brain—primarily through inhibition of dopamine reuptake via binding to the dopamine transporter, leading to increased extracellular dopamine levels. It may also activate orexin neurons in the hypothalamus and influence glutamatergic circuits while inhibiting GABAergic activity. Unlike traditional stimulants such as amphetamines, modafinil has a distinct chemical structure and lower potential for euphoria or abuse but is still classified as a Schedule IV controlled substance due to some risk of misuse[1][2][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on modafinil.